KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Longitudinal trajectories of anxiety and depression in patients with endometrial cancer or atypical endometrial hyperplasia undergoing fertility-sparing treatment. PMID 42139817 · Gynecol Oncol · 2026-Jun Eligible for oncology, human, randomized, drug intervention, and original result. Excluded because the primary endpoint is psychological outcomes (anxiety/depression), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC. PMID 42120266 · Clin Lung Cancer · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Distal margin length after neoadjuvant chemoradiotherapy has no prognostic impact in low rectal cancer once the margin is microscopically negative: A multicentre equivalence analysis. PMID 42114353 · Eur J Surg Oncol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Twenty-Three-Year Benefits of Sigmoidoscopy Screening for Colorectal Cancer : A Randomized Trial. PMID 42114097 · Ann Intern Med · 2026-Jun The record describes a randomized, population-based cancer screening trial evaluating sigmoidoscopy for colorectal cancer incidence and mortality reduction. While it is oncology and reports long-term results, it does not meet the required criteria: it is not a Phase III/IIIb or Phase II/III trial (no drug intervention is involved), and it does not report a primary/time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) for a drug. The outcomes are cancer incidence and mortality risk differences, not time-to-event analyses with Kaplan-Meier curves or hazard ratios as primary endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial. PMID 42070197 · Dermatol Ther (Heidelb) · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Get a grip! - Baseline handgrip strength and sarcopenia as predictors of survival in patients with head and neck squamous cell carcinoma. PMID 42069057 · Clin Nutr ESPEN · 2026-Jun The record describes an observational sub-study of a randomized trial. The parent trial's intervention is described as a 'randomized nutritional intervention', and the sub-study analyzes associations of baseline HGS/sarcopenia with survival. While it is oncology, human, randomized, and reports time-to-event efficacy (OS with HR and KM), it does not meet the requirement of a drug-containing intervention. The phase is not explicitly stated in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Identifying Symptom Clusters for Acute Dermatitis-Exploratory Analysis of a Randomized Control Trial Comparing Mepitel Film and Standard of Care for the Prevention of Radiation Dermatitis. PMID 42066679 · Clin Breast Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA). PMID 42058637 · ESMO Gastrointest Oncol · 2026-Jun This is a protocol/design description for an ongoing open-label, non-randomized Phase Ib/II platform trial. It does not report results of a randomized trial, is not Phase III, and lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) in the abstract.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of selpercatinib as a first-line treatment for RET-fusion positive non-small-cell lung cancer: a novel two-stage Bayesian network meta-analysis. PMID 42052748 · J Comp Eff Res · 2026-Jun The record is a network meta-analysis that uses data from single-arm and other trials to model comparative effectiveness. It is not an original, formal-result report of a randomized, controlled trial with a drug-containing intervention and a primary time-to-event endpoint. The publication types include Phase I/II, and the study is not a definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of gradient compression sleeves in preventing postoperative upper extremity lymphoedema after breast cancer surgery. PMID 42051193 · Expert Rev Med Devices · 2026-Jun The study is an oncology randomized controlled trial evaluating a medical device (compression sleeves) for preventing lymphedema after breast cancer surgery. It lacks a drug intervention and a primary time-to-event efficacy endpoint (e.g., survival, progression).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial. PMID 42032072 · Nat Med · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors. PMID 42026180 · Leukemia · 2026-Jun The study is a non-comparative Phase IIIb trial in oncology (CML-CP) with a drug intervention (asciminib), but it is not randomized and its primary efficacy endpoint is a binary response rate (MMR rate), not a time-to-event outcome like OS, PFS, or DFS. No Kaplan-Meier or HR for such an endpoint is reported.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Seven-day Venetoclax Combined With Dose-adjusted Intensive Chemotherapy as Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia. PMID 42002452 · Clin Lymphoma Myeloma Leuk · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis of the randomized clinical trial (JASPAC-01). PMID 41991754 · J Gastroenterol · 2026-Jun The record describes an exploratory analysis of a randomized trial (JASPAC-01) focused on a dosage formula's relationship to adverse events and dose reduction. While the trial itself is oncology, human, randomized, involves a drug intervention (S-1), and includes a time-to-event outcome (5-year overall survival), this specific report is not a primary or key secondary efficacy analysis of the trial. It is a secondary, post-hoc, or safety-focused analysis, which is excluded per the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia in Denmark: an open-label, randomised controlled trial. PMID 41990768 · Lancet Child Adolesc Health · 2026-Jun The record is an original RCT in oncology patients, but it is ineligible due to lack of a drug-containing intervention (it compares durations of existing antibiotic therapy, not a novel drug vs. control) and absence of a primary time-to-event efficacy endpoint (OS, PFS, etc.) with KM or HR reporting.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Pilot Randomized Cross-Over Trial Focused on Colonoscopy Skill Acquisition Using High Fidelity Versus Low Fidelity Simulators in Nigeria. PMID 41990515 · J Surg Educ · 2026-Jun This is a pilot randomized crossover trial comparing colonoscopy simulation training methods (high-fidelity vs. low-fidelity) in a medical education context. While it mentions colorectal cancer as background, the study itself is not a therapeutic intervention trial for cancer, does not involve a drug, is not Phase III, and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier curve).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. PMID 41990460 · Semin Arthritis Rheum · 2026-Jun This is an observational study (target trial emulation using Medicare data) comparing antirheumatic drugs for rheumatoid arthritis-associated interstitial lung disease. It is not an oncology study, not a randomized trial, and does not report on a primary/key secondary time-to-event efficacy endpoint from a Phase III/IIIb or Phase II/III randomized drug trial for human malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Imperial Prostate 9 - Approaches To Long-term Active Surveillance: Regular MRI scans versus standard of care (IP9-ATLAS) randomised controlled trial. PMID 41990428 · Contemp Clin Trials · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. PMID 41989666 · Int J Clin Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized Trial. PMID 41986965 · Cancer Sci · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. PMID 41986167 · Clin Lymphoma Myeloma Leuk · 2026-Jun The record describes a Phase III randomized trial in Hodgkin lymphoma with drug interventions, but the reported endpoints are patient-reported outcomes for chemotherapy-induced peripheral neuropathy and quality of life. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR for survival) is reported. Therefore, it does not meet the key criterion for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. PMID 41978554 · Br J Haematol · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). PMID 41962116 · J Clin Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Promising efficacy of coenzyme Q10 supplementation as adjunctive therapy in juvenile idiopathic arthritis: a randomized-controlled pilot study. PMID 41958203 · Immunopharmacol Immunotoxicol · 2026-Jun This record is an original randomized controlled trial (Phase II/III) in humans, but it fails multiple key eligibility criteria: 1) It is not an oncology/malignant neoplasm study (juvenile idiopathic arthritis). 2) The intervention is a dietary supplement (CoQ10), not a drug. 3) The primary efficacy endpoint is a disease activity score (JADAS-10), not a time-to-event endpoint like OS, PFS, etc. No Kaplan-Meier or HR is reported. Therefore, it is ineligible.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of scalp cooling system versus chemical cooling cap in preventing chemotherapy-induced alopecia in breast cancer (COHAIR Study): a prospective randomized trial. PMID 41955993 · Breast · 2026-Jun The trial is a randomized, prospective study in oncology patients, but its primary efficacy endpoint is the prevention of chemotherapy-induced alopecia (a supportive care outcome), not a key time-to-event efficacy endpoint (like OS, PFS, DFS) for the cancer itself. The mention of DFS as comparable is incidental and not the primary focus. The trial phase is not confirmed to be Phase III or definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
STRASS 2 target trial emulation: Bridging the gap between trial efficacy and real-world effectiveness. PMID 41936769 · Surgery · 2026-Jun The record is a target trial emulation study using real-world data to evaluate the STRASS 2 trial's concept. It is not the original report of a Phase III/IIIb or Phase II/III randomized clinical trial. The study itself is observational and retrospective, not a prospective randomized trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. PMID 41934464 · J Thorac Oncol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of oral nutritional supplements on nutritional outcomes and survival in post-gastrectomy patients receiving chemotherapy. PMID 41912109 · Clin Nutr ESPEN · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. PMID 41903611 · Radiother Oncol · 2026-Jun 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L B
旧查询独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). PMID 41864056 · Breast · 2026-Jun This is a randomized, controlled, oncology trial with a drug intervention and a time-to-event endpoint (RFS). However, the report is explicitly a biomarker subgroup analysis within a larger trial (MATADOR). The criteria require inclusion of only 'original formal-result reports' for the overall trial population, not post-hoc or biomarker-only analyses. The phase is not explicitly stated as Phase III/IIIb or II/III in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A multidomain perioperative intervention improves postoperative recovery and clinical outcomes after abdominoperineal resection for low rectal cancer: A randomized controlled trial. PMID 41849835 · Am J Surg · 2026-Jun The trial is a randomized, human, oncology study with a primary time-to-event endpoint (DFS). However, the intervention is a non-drug behavioral/cognitive therapy integrated into ERAS, not a drug-containing intervention, which is a required criterion. There is also no explicit evidence of Phase III/IIIb or Phase II/III status in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Pain Relief in Patients Undergoing Elective Laparoscopic Gastrointestinal Tumor Surgery. PMID 41824217 · Pain Ther · 2026-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. PMID 41821360 · Prostate · 2026-Jun The study is a randomized, human, oncology-related trial with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The analysis focuses on LUTS incidence/progression as a secondary outcome, making it ineligible for the KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41817930 · Ann Surg Oncol · 2026-Jun The trial is a Phase 3, randomized, placebo-controlled oncology trial with a drug intervention. However, based on the provided metadata (title indicates it's about surgical outcomes after neoadjuvant treatment), the primary or key secondary endpoint appears to be a pathological/surgical outcome (e.g., pathological complete response), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it fails the 'time_to_event' criterion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem‑ion): Interim report of a randomized phase II pilot trial. PMID 41812864 · Radiother Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of a three-step dose escalation regimen of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: a phase 3b, single-arm, multicenter study. PMID 41801560 · Int J Hematol · 2026-Jun 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced pancreatic cancer: A single-center randomized controlled trial. PMID 41794391 · Clin Nutr ESPEN · 2026-Jun The record is a Phase II/III randomized trial (indicated by trial registration UMIN000028659, which is a Phase III study) with a drug-containing intervention (chemotherapy) and primary time-to-event efficacy endpoints (OS, PFS). However, the specific intervention being evaluated (elemental diet) is a nutritional supplement, not a drug. The cohort definition requires a 'drug-containing intervention' as the key element of the trial. While chemotherapy is present in both arms, the trial is designed to evaluate the effect of adding an elemental diet to standard chemotherapy. The primary intervention is not a drug. Therefore, it is excluded based on the 'drug_intervention' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Short-term isolated leucine supplementation was not associated with improvements in muscle mass or function in patients with head and neck cancer: A randomized, double-blind, proof-of-concept trial with an elderly non-cancer comparator cohort. PMID 41786247 · Clin Nutr ESPEN · 2026-Jun The study is a randomized, double-blind, proof-of-concept trial evaluating leucine supplementation for cancer cachexia. It is oncology-related, human, randomized, and has a drug intervention. However, it is not a Phase III/IIIb or Phase II/III trial (it's a proof-of-concept study), and its primary endpoint is change in muscle mass (a biological/functional measure), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. Therefore, it does not meet the core eligibility criteria for this adjudication.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Scoping review: Investigating target trial emulation approaches in oncology research. PMID 41762536 · Cancer Epidemiol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41739398 · Ann Surg Oncol · 2026-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Dietary advice alone or with oral nutritional supplements after hospital discharge in colorectal cancer surgery patients: Five year follow-up of a randomized controlled trial. PMID 41719951 · Nutrition · 2026-Jun The record is excluded because the intervention lacks a drug component (it is a non-drug nutritional intervention), which is a mandatory inclusion criterion. The phase of the trial is also not explicitly established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of the Effect of Intravenous Lidocaine on the Systemic Inflammatory Response Associated With Cardiopulmonary Bypass in Valvular and/or Coronary Cardiac Surgery: Protocol for a Double-Blind Randomized Clinical Trial. PMID 41690863 · J Cardiothorac Vasc Anesth · 2026-Jun The record is a clinical trial protocol for a study in cardiac surgery (non-oncology). It does not report results, is not a Phase III/IIIb trial, and its primary endpoint is a biomarker (IL-6 level), not a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34. PMID 41644375 · Eur Urol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Durvalumab in Combination with BCG for BCG-naive, High risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial. PMID 41638957 · Eur Urol · 2026-Jun The title establishes oncology, randomized Phase 3, and drug intervention, but the abstract is blank, so human subject status, time-to-event endpoint, and original result status cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Main factors associated with variability in the assessment of the objective response rate. A re-analysis of the PHEREXA phase 3 clinical trial. PMID 41619193 · Br J Clin Pharmacol · 2026-Jun This is a secondary analysis of the PHEREXA phase 3 trial focusing on methodological aspects of objective response rate (ORR) assessment (inter-reader variability), not the primary or key secondary time-to-event efficacy outcomes (e.g., OS, PFS). While the underlying trial was phase 3, this report does not present Kaplan-Meier curves or hazard ratios for survival or progression endpoints. The drug intervention is not specified in this re-analysis abstract, and it is a post-hoc methodological study, not an original primary result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. PMID 41611210 · Ann Oncol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34. PMID 41558887 · Eur Urol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Integrated psychosocial, sleep, and nutritional support improves postoperative recovery, immune modulation, and survival after curative resection for low rectal cancer: A randomized controlled trial. PMID 41475954 · Am J Surg · 2026-Jun The record describes a randomized trial in human oncology with time-to-event endpoints (DFS, OS). However, it fails two required criteria: (1) The intervention is explicitly non-pharmacologic (psychosocial, sleep, nutritional support), not a drug-containing intervention. (2) The trial phase is not specified in the provided metadata or abstract as Phase III/IIIb or Phase II/III. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO). PMID 41469270 · Eur Urol Oncol · 2026-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Design and rationale of the ZORALCS study: An implementation study of lung cancer screening by low-dose computed tomography coupled to a smoking cessation randomized controlled trial in the Flemish region. PMID 41468155 · J Med Screen · 2026-Jun The record is a study protocol for a non-randomized, population-based feasibility study of lung cancer screening, not a randomized drug trial with time-to-event efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -